Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia

References

• Dameshek W. Chronic lymphocytic leukemia–an accumulative disease of immunolgically incompetent lymphocytes. Blood 1967; 29: Suppl:566-84; PMID:6022294
   PubMedGoogle Scholar
• Phillips JA, Mehta K, Fernandez C, Raveche ES. The NZB mouse as a model for chronic lymphocytic leukemia. Cancer Res 1992; 52:437-43; PMID:1370214
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 2011; 117:1781-91; PMID:21148333; http://dx.doi.org/10.1182/blood-2010-07-155663
   PubMed Web of Science ®Google Scholar
• Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, Freedman A, Inghirami G, Cro L, Baldini L et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194:1625-38; PMID:11733577; http://dx.doi.org/10.1084/jem.194.11.1625
   PubMed Web of Science ®Google Scholar
• Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Durig J, Kuppers R. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 2012; 209:2183-98; PMID:23091163; http://dx.doi.org/10.1084/jem.20120833
   PubMed Web of Science ®Google Scholar
• Forconi F, Potter KN, Wheatley I, Darzentas N, Sozzi E, Stamatopoulos K, Mockridge CI, Packham G, Stevenson FK. The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. Blood 2010; 115:71-7; PMID:19887677; http://dx.doi.org/10.1182/blood-2009-06-225813
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Weinberg JB, Yoshizaki A, Horikawa M, Bryant JM, Iwata Y, Matsushita T, Matta KM, Chen Y, Venturi GM et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia 2013; 27:170-82; PMID:22713648; http://dx.doi.org/10.1038/leu.2012.165
   PubMed Web of Science ®Google Scholar
• Jadidi-Niaragh F, Yousefi M, Memarian A, Hojjat-Farsangi M, Khoshnoodi J, Razavi SM, Jeddi-Tehrani M, Shokri F. Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression. Cancer Invest 2013; 31:121-31; PMID:23286587; http://dx.doi.org/10.3109/07357907.2012.756110
   PubMed Web of Science ®Google Scholar
• Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 2013; 122:3723-34; PMID:24065239; http://dx.doi.org/10.1182/blood-2013-05-498287
   PubMed Web of Science ®Google Scholar
• Carter NA, Vasconcellos R, Rosser EC, Tulone C, Munoz-Suano A, Kamanaka M, Ehrenstein MR, Flavell RA, Mauri C. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol 2011; 186:5569-79; PMID:21464089; http://dx.doi.org/10.4049/jimmunol.1100284
   PubMed Web of Science ®Google Scholar
• Matsushita T, Horikawa M, Iwata Y, Tedder TF. Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol 2010; 185:2240-52; PMID:20624940; http://dx.doi.org/10.4049/jimmunol.1001307
   PubMed Web of Science ®Google Scholar
• Wong SC, Puaux AL, Chittezhath M, Shalova I, Kajiji TS, Wang X, Abastado JP, Lam KP, Biswas SK. Macrophage polarization to a unique phenotype driven by B cells. Eur J Immunol 2010; 40:2296-307; PMID:20468007; http://dx.doi.org/10.1002/eji.200940288
   PubMed Web of Science ®Google Scholar
• Carter NA, Rosser EC, Mauri C. Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res Ther 2012; 14:R32; PMID:22315945; http://dx.doi.org/10.1186/ar3736
   PubMed Web of Science ®Google Scholar
• Flores-Borja F, Bosma A, Ng D, Reddy V, Ehrenstein MR, Isenberg DA, Mauri C. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 2013; 5:173ra23; PMID:23427243; http://dx.doi.org/10.1126/scitranslmed.3005407
   PubMed Web of Science ®Google Scholar
• Loder F, Mutschler B, Ray RJ, Paige CJ, Sideras P, Torres R, Lamers MC, Carsetti R. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med 1999; 190:75-89; PMID:10429672; http://dx.doi.org/10.1084/jem.190.1.75
   PubMed Web of Science ®Google Scholar
• Lehuen A, Lantz O, Beaudoin L, Laloux V, Carnaud C, Bendelac A, Bach JF, Monteiro RC. Overexpression of natural killer T cells protects Valpha14- Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998; 188:1831-9; PMID:9815260; http://dx.doi.org/10.1084/jem.188.10.1831
   PubMed Web of Science ®Google Scholar
• Saubermann LJ, Beck P, De Jong YP, Pitman RS, Ryan MS, Kim HS, Exley M, Snapper S, Balk SP, Hagen SJ et al. Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 2000; 119:119-28; PMID:10889161; http://dx.doi.org/10.1053/gast.2000.9114
   PubMed Web of Science ®Google Scholar
• Olkhanud PB, Rochman Y, Bodogai M, Malchinkhuu E, Wejksza K, Xu M, Gress RE, Hesdorffer C, Leonard WJ, Biragyn A. Thymic stromal lymphopoietin is a key mediator of breast cancer progression. J Immunol 2011; 186:5656-62; PMID:21490155; http://dx.doi.org/10.4049/jimmunol.1100463
   PubMed Web of Science ®Google Scholar
• He Y, Qian H, Liu Y, Duan L, Li Y, Shi G. The roles of regulatory B cells in cancer. J Immunol Res 2014; 2014:215471; PMID:24991577
   PubMedGoogle Scholar
• Lindner S, Dahlke K, Sontheimer K, Hagn M, Kaltenmeier C, Barth TF, Beyer T, Reister F, Fabricius D, Lotfi R et al. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res 2013; 73:2468-79; PMID:23384943; http://dx.doi.org/10.1158/0008-5472.CAN-12-3450
   PubMed Web of Science ®Google Scholar
• Chesneau M, Michel L, Dugast E, Chenouard A, Baron D, Pallier A, Durand J, Braza F, Guerif P, Laplaud DA et al. Tolerant kidney transplant patients produce B cells with regulatory properties. J Am Soc Nephrol 2015; 26:2588-98; PMID:25644114; http://dx.doi.org/10.1681/ASN.2014040404
   PubMed Web of Science ®Google Scholar
• Braza F, Chesne J, Castagnet S, Magnan A, Brouard S. Regulatory functions of B cells in allergic diseases. Allergy 2014; 69:1454-63; PMID:25060230; http://dx.doi.org/10.1111/all.12490
   PubMed Web of Science ®Google Scholar
• Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002; 16:219-30; PMID:11869683; http://dx.doi.org/10.1016/S1074-7613(02)00274-1
   PubMed Web of Science ®Google Scholar
• Miles K, Heaney J, Sibinska Z, Salter D, Savill J, Gray D, Gray M. A tolerogenic role for Toll-like receptor 9 is revealed by B-cell interaction with DNA complexes expressed on apoptotic cells. Proc Natl Acad Sci U S A 2012; 109:887-92; PMID:22207622; http://dx.doi.org/10.1073/pnas.1109173109
   PubMed Web of Science ®Google Scholar
• Kalampokis I, Yoshizaki A, Tedder TF. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther 2013; 15 Suppl 1:S1; PMID:23566714; http://dx.doi.org/10.1186/ar3907
   PubMed Web of Science ®Google Scholar
• Yang X, Yang J, Chu Y, Wang J, Guan M, Zhu X, Xue Y, Zou H. T follicular helper cells mediate expansion of regulatory B cells via IL-21 in Lupus-prone MRL/lpr mice. PLoS One 2013; 8:e62855; PMID:23638156; http://dx.doi.org/10.1371/journal.pone.0062855
   PubMedGoogle Scholar
• Matsumoto M, Fujii Y, Baba A, Hikida M, Kurosaki T, Baba Y. The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production. Immunity 2011; 34:703-14; PMID:21530328; http://dx.doi.org/10.1016/j.immuni.2011.03.016
   PubMed Web of Science ®Google Scholar
• Garaud S, Morva A, Lemoine S, Hillion S, Bordron A, Pers JO, Berthou C, Mageed RA, Renaudineau Y, Youinou P. CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol 2011; 186:4835-44; PMID:21398617; http://dx.doi.org/10.4049/jimmunol.1003050
   PubMed Web of Science ®Google Scholar
• Noh G, Lee JH. Regulatory B cells and allergic diseases. Allergy Asthma Immunol Res 2011; 3:168-77; PMID:21738882; http://dx.doi.org/10.4168/aair.2011.3.3.168
   PubMed Web of Science ®Google Scholar
• Snir A, Kessel A, Haj T, Rosner I, Slobodin G, Toubi E. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy. Clin Exp Rheumatol 2011; 29:697-700; PMID:21813064
   PubMed Web of Science ®Google Scholar
• Yoshizaki A, Miyagaki T, DiLillo DJ, Matsushita T, Horikawa M, Kountikov EI, Spolski R, Poe JC, Leonard WJ, Tedder TF. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 2012; 491:264-8; PMID:23064231; http://dx.doi.org/10.1038/nature11501
   PubMed Web of Science ®Google Scholar
• Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 2004; 172:3422-7; PMID:15004141; http://dx.doi.org/10.4049/jimmunol.172.6.3422
   PubMed Web of Science ®Google Scholar
• Stang SL, Lopez-Campistrous A, Song X, Dower NA, Blumberg PM, Wender PA, Stone JC. A proapoptotic signaling pathway involving RasGRP, Erk, and Bim in B cells. Exp Hematol 2009; 37:122-34; PMID:19100522; http://dx.doi.org/10.1016/j.exphem.2008.09.008
   PubMed Web of Science ®Google Scholar
• Tomic J, White D, Shi Y, Mena J, Hammond C, He L, Miller RL, Spaner DE. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol 2006; 176:3830-9; PMID:16517754; http://dx.doi.org/10.4049/jimmunol.176.6.3830
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Yoshizaki A, Simon KL, Kirby MR, Anderson SM, Candotti F. Age-dependent defects of regulatory B cells in Wiskott-Aldrich syndrome gene knockout mice. PLoS One 2015; 10:e0139729; PMID:26448644; http://dx.doi.org/10.1371/journal.pone.0139729
   PubMedGoogle Scholar
• Mittal AK, Chaturvedi NK, Rai KJ, Gilling-Cutucache CE, Nordgren TM, Moragues M, Lu R, Opavsky R, Bociek GR, Weisenburger DD et al. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease. Mol Med 2014; 20:290-301; PMID:24800836; http://dx.doi.org/10.2119/molmed.2012.00303
   PubMed Web of Science ®Google Scholar
• Spaner DE, Shi Y, White D, Mena J, Hammond C, Tomic J, He L, Tomai MA, Miller RL, Booth J et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2006; 20:286-95; PMID:16341037; http://dx.doi.org/10.1038/sj.leu.2404061
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, Byrd JC, Gribben JG. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118:2427-37; PMID:18551193; http://dx.doi.org/10.1172/JCI35017
   PubMed Web of Science ®Google Scholar
• Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005; 115:1797-805; PMID:15965501; http://dx.doi.org/10.1172/JCI24176
   PubMed Web of Science ®Google Scholar
• Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L, Jaksic O, Fedele G, Inghirami G, Gaidano G et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica 2013; 98:953-63; PMID:23300177; http://dx.doi.org/10.3324/haematol.2012.077537
   PubMed Web of Science ®Google Scholar
• Os A, Bürgler S, Ribes Anna P, Funderud A, Wang D, Thompson Keith M, Tjønnfjord Geir E, Bogen B, Munthe Ludvig A. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Rep 2013; 4:566-77; PMID:23933259; http://dx.doi.org/10.1016/j.celrep.2013.07.011
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, Knolle PA, Thomas RK, von Bergwelt-Baildon M, Debey S et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106:2018-25; PMID:15914560; http://dx.doi.org/10.1182/blood-2005-02-0642
   PubMed Web of Science ®Google Scholar
• Lindqvist CA, Christiansson LH, Simonsson B, Enblad G, Olsson-Stromberg U, Loskog AS. T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology 2010; 131:371-6; PMID:20518821; http://dx.doi.org/10.1111/j.1365-2567.2010.03308.x
   PubMed Web of Science ®Google Scholar
• Christopoulos P, Pfeifer D, Bartholome K, Follo M, Timmer J, Fisch P, Veelken H. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood 2011; 117:3836-46; PMID:21270444; http://dx.doi.org/10.1182/blood-2010-07-299321
   PubMed Web of Science ®Google Scholar
• Bojarska-Junak A, Hus I, Chocholska S, Tomczak W, Wos J, Czubak P, Putowski L, Rolinski J. CD1d expression is higher in chronic lymphocytic leukemia patients with unfavorable prognosis. Leuk Res 2014; 38:435-42; PMID:24418751; http://dx.doi.org/10.1016/j.leukres.2013.12.015
   PubMed Web of Science ®Google Scholar
• Weinkove R, Brooks CR, Carter JM, Hermans IF, Ronchese F. Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy. Haematologica 2013; 98:376-84; PMID:23065503; http://dx.doi.org/10.3324/haematol.2012.072835
   PubMed Web of Science ®Google Scholar
• Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4:231-7; PMID:15039760; http://dx.doi.org/10.1038/nri1309
   PubMed Web of Science ®Google Scholar
• Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25:297-336; PMID:17150027; http://dx.doi.org/10.1146/annurev.immunol.25.022106.141711
   PubMed Web of Science ®Google Scholar
• Blomqvist M, Rhost S, Teneberg S, Lofbom L, Osterbye T, Brigl M, Mansson JE, Cardell SL. Multiple tissue-specific isoforms of sulfatide activate CD1d-restricted type II NKT cells. Eur J Immunol 2009; 39:1726-35; PMID:19582739; http://dx.doi.org/10.1002/eji.200839001
   PubMed Web of Science ®Google Scholar
• Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010; 11:197-206; PMID:20139988; http://dx.doi.org/10.1038/ni.1841
   PubMed Web of Science ®Google Scholar
• Fais F, Morabito F, Stelitano C, Callea V, Zanardi S, Scudeletti M, Varese P, Ciccone E, Grossi CE. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. Int J Cancer 2004; 109:402-11; PMID:14961579; http://dx.doi.org/10.1002/ijc.11723
   PubMed Web of Science ®Google Scholar
• Jadidi-Niaragh F, Jeddi-Tehrani M, Ansaripour B, Razavi SM, Sharifian RA, Shokri F. Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia. Med Oncol 2012; 29:3561-9; PMID:22669567; http://dx.doi.org/10.1007/s12032-012-0262-4
   PubMed Web of Science ®Google Scholar
• Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, Gregory SA. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 2008; 22:998-1006; PMID:18288133; http://dx.doi.org/10.1038/leu.2008.15
   PubMed Web of Science ®Google Scholar
• Itala M, Vainio O, Remes K. Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia. Eur J Haematol 1996; 57:46-53; PMID:8698131; http://dx.doi.org/10.1111/j.1600-0609.1996.tb00489.x
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Georgiadou SP, Wierda WG, Wright S, Albert ND, Ferrajoli A, Keating M, Lewis RE. Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2013; 54:1730-3; PMID:23163595; http://dx.doi.org/10.3109/10428194.2012.750723
   PubMed Web of Science ®Google Scholar
• Messmer D, Telusma G, Wasil T, Messmer BT, Allen S, Rai KR, Chiorazzi N. Dendritic cells from chronic lymphocytic leukemia patients are normal regardless of Ig V gene mutation status. Mol Med 2004; 10:96-103; PMID:16113842
   PubMed Web of Science ®Google Scholar
• Saulep-Easton D, Vincent FB, Le Page M, Wei A, Ting SB, Croce CM, Tam C, Mackay F. Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia. Leukemia 2014; 28:2005-15; PMID:24721775; http://dx.doi.org/10.1038/leu.2014.105
   PubMed Web of Science ®Google Scholar
• Gustafson MP, Abraham RS, Lin Y, Wu W, Gastineau DA, Zent CS, Dietz AB. Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). Br J Haematol 2012; 156:674-6; PMID:22050346; http://dx.doi.org/10.1111/j.1365-2141.2011.08902.x
   PubMed Web of Science ®Google Scholar
• Jitschin R, Braun M, Buttner M, Dettmer-Wilde K, Bricks J, Berger J, Eckart MJ, Krause SW, Oefner PJ, Le Blanc K et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 2014; 124:750-60; PMID:24850760; http://dx.doi.org/10.1182/blood-2013-12-546416
   PubMed Web of Science ®Google Scholar
• Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol 2012; 30:221-41; PMID:22224776; http://dx.doi.org/10.1146/annurev-immunol-020711-074934
   PubMed Web of Science ®Google Scholar
• Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010; 32:129-40; PMID:20079667; http://dx.doi.org/10.1016/j.immuni.2009.11.009
   PubMed Web of Science ®Google Scholar
• Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011; 117:530-41; PMID:20962324; http://dx.doi.org/10.1182/blood-2010-07-294249
   PubMed Web of Science ®Google Scholar
• Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008; 28:639-50; PMID:18482568; http://dx.doi.org/10.1016/j.immuni.2008.03.017
   PubMed Web of Science ®Google Scholar
• Qian L, Qian C, Chen Y, Bai Y, Bao Y, Lu L, Cao X. Regulatory dendritic cells program B cells to differentiate into CD19hiFcgammaIIbhi regulatory B cells through IFN-beta and CD40L. Blood 2012; 120:581-91; PMID:22692512; http://dx.doi.org/10.1182/blood-2011-08-377242
   PubMed Web of Science ®Google Scholar
• Blair PA, Chavez-Rueda KA, Evans JG, Shlomchik MJ, Eddaoudi A, Isenberg DA, Ehrenstein MR, Mauri C. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol 2009; 182:3492-502; PMID:19265127; http://dx.doi.org/10.4049/jimmunol.0803052
   PubMed Web of Science ®Google Scholar
• Saulep-Easton D, Vincent FB, Quah PS, Wei A, Ting SB, Croce CM, Tam C, Mackay F. The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells. Leukemia 2015; PMID:26139429; http://dx.doi.org/10.138/leu.2015
   PubMedGoogle Scholar
• Puiggros A, Blanco G, Espinet B. Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go. Biomed Res Int 2014; 2014:435983; PMID:24967369; http://dx.doi.org/10.1155/2014/435983
   PubMed Web of Science ®Google Scholar
• Karmali R, Paganessi LA, Frank RR, Jagan S, Larson ML, Venugopal P, Gregory SA, Christopherson KW, 2nd. Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. J Leukoc Biol 2013; 93:161-70; PMID:23136257; http://dx.doi.org/10.1189/jlb.0612301
   PubMed Web of Science ®Google Scholar
• Deaglio S, Capobianco A, Bergui L, Durig J, Morabito F, Duhrsen U, Malavasi F. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003; 102:2146-55; PMID:12763926; http://dx.doi.org/10.1182/blood-2003-03-0989
   PubMed Web of Science ®Google Scholar
• Vaisitti T, Aydin S, Rossi D, Cottino F, Bergui L, D'Arena G, Bonello L, Horenstein AL, Brennan P, Pepper C et al. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 2010; 24:958-69; PMID:20220774; http://dx.doi.org/10.1038/leu.2010.36
   PubMed Web of Science ®Google Scholar
• Vaisitti T, Audrito V, Serra S, Buonincontri R, Sociali G, Mannino E, Pagnani A, Zucchetto A, Tissino E, Vitale C et al. The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. Leukemia 2015; 29:356-68; PMID:24990614; http://dx.doi.org/10.1038/leu.2014.207
   PubMed Web of Science ®Google Scholar
• Zupo S, Isnardi L, Megna M, Massara R, Malavasi F, Dono M, Cosulich E, Ferrarini M. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 1996; 88:1365-74; PMID:8695855
   PubMed Web of Science ®Google Scholar
• Jahrsdorfer B, Blackwell SE, Wooldridge JE, Huang J, Andreski MW, Jacobus LS, Taylor CM, Weiner GJ. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 2006; 108:2712-9; PMID:16809616; http://dx.doi.org/10.1182/blood-2006-03-014001
   PubMed Web of Science ®Google Scholar
• Hagn M, Blackwell SE, Beyer T, Ebel V, Fabricius D, Lindner S, Stilgenbauer S, Simmet T, Tam C, Neeson P et al. B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21. Int Immunol 2014; 26:383-95; PMID:24497611; http://dx.doi.org/10.1093/intimm/dxu001
   PubMed Web of Science ®Google Scholar
• Wlasiuk P, Tomczak W, Zajac M, Dmoszynska A, Giannopoulos K. Total expression of HLA-G and TLR-9 in chronic lymphocytic leukemia patients. Hum Immunol 2013; 74:1592-7; PMID:23994589; http://dx.doi.org/10.1016/j.humimm.2013.08.277
   PubMed Web of Science ®Google Scholar
• Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HT, Beers SA, French RR, Cox KL, Davies AJ et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011; 118:2530-40; PMID:21768293; http://dx.doi.org/10.1182/blood-2011-01-330357
   PubMed Web of Science ®Google Scholar
• Ferrer G, Bosch R, Hodgson K, Tejero R, Roue G, Colomer D, Montserrat E, Moreno C. B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL. Br J Haematol 2014; 164:570-8; PMID:24245956; http://dx.doi.org/10.1111/bjh.12645
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33; PMID:9704735
   PubMed Web of Science ®Google Scholar
• Huh YO, Keating MJ, Saffer HL, Jilani I, Lerner S, Albitar M. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 2001; 116:437-43; PMID:11554173; http://dx.doi.org/10.1309/438N-E0FH-A5PR-XCAC
   PubMed Web of Science ®Google Scholar
• Shaha SP, Tomic J, Shi Y, Pham T, Mero P, White D, He L, Baryza JL, Wender PA, Booth JW et al. Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells. Clin Exp Immunol 2009; 158:186-98; PMID:19737143; http://dx.doi.org/10.1111/j.1365-2249.2009.04003.x
   PubMed Web of Science ®Google Scholar
• Hosing C, Kebriaei P, Wierda W, Jena B, Cooper LJ, Shpall E. CARs in chronic lymphocytic leukemia – ready to drive. Curr Hematol Malig Rep 2013; 8:60-70; PMID:23225251; http://dx.doi.org/10.1007/s11899-012-0145-y
   PubMed Web of Science ®Google Scholar
• Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006; 66:10995-1004; PMID:17108138; http://dx.doi.org/10.1158/0008-5472.CAN-06-0160
   PubMed Web of Science ®Google Scholar
• Benoit NE, Wade WF. Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin. Immunopharmacology 1996; 35:129-39; PMID:8956976; http://dx.doi.org/10.1016/S0162-3109(96)00138-5
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53:2136-42; PMID:22475052; http://dx.doi.org/10.3109/10428194.2012.681655
   PubMed Web of Science ®Google Scholar
• Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96:2917-24; PMID:11049967
   PubMed Web of Science ®Google Scholar
• Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998; 101:1133-41; PMID:9486984; http://dx.doi.org/10.1172/JCI1472
   PubMed Web of Science ®Google Scholar
• Pallasch CP, Ulbrich S, Brinker R, Hallek M, Uger RA, Wendtner CM. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk Res 2009; 33:460-4; PMID:18838168; http://dx.doi.org/10.1016/j.leukres.2008.08.021
   PubMed Web of Science ®Google Scholar
• Gorczynski RM, Lee L, Boudakov I. Augmented induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R. Transplantation 2005; 79:488-91; PMID:15729177; http://dx.doi.org/10.1097/01.TP.0000152118.51622.F9
   PubMed Web of Science ®Google Scholar
• McWhirter JR, Kretz-Rommel A, Saven A, Maruyama T, Potter KN, Mockridge CI, Ravey EP, Qin F, Bowdish KS. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci U S A 2006; 103:1041-6; PMID:16418292; http://dx.doi.org/10.1073/pnas.0510081103
   PubMed Web of Science ®Google Scholar
• Laprevotte E, Voisin G, Ysebaert L, Klein C, Daugrois C, Laurent G, Fournie JJ, Quillet-Mary A. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy. J Immunol 2013; 191:3634-40; PMID:23997218; http://dx.doi.org/10.4049/jimmunol.1300187
   PubMed Web of Science ®Google Scholar
• Moga E, Alvarez E, Canto E, Vidal S, Rodriguez-Sanchez JL, Sierra J, Briones J. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol 2008; 36:69-77; PMID:17959301; http://dx.doi.org/10.1016/j.exphem.2007.08.012
   PubMed Web of Science ®Google Scholar
• Moga E, Canto E, Vidal S, Juarez C, Sierra J, Briones J. Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression. Exp Hematol 2011; 39:1064-71; PMID:21864486; http://dx.doi.org/10.1016/j.exphem.2011.08.006
   PubMed Web of Science ®Google Scholar
• Wild J, Schmiedel BJ, Maurer A, Raab S, Prokop L, Stevanovic S, Dorfel D, Schneider P, Salih HR. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis. Leukemia 2015; 29:1676-83; PMID:25710310; http://dx.doi.org/10.1038/leu.2015.50
   PubMed Web of Science ®Google Scholar
• Junevik K, Werlenius O, Fogelstrand L, Karlsson-Parra A, Andersson PO. High functional CD70 expression on alpha-type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia. Scand J Immunol 2014; 79:415-22; PMID:24684541; http://dx.doi.org/10.1111/sji.12172
   PubMed Web of Science ®Google Scholar
• Riches JC, Ramsay AG, Gribben JG. Immune reconstitution in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2012; 7:13-20; PMID:22231031; http://dx.doi.org/10.1007/s11899-011-0106-x
   PubMed Web of Science ®Google Scholar
• Golay J, D'Amico A, Borleri G, Bonzi M, Valgardsdottir R, Alzani R, Cribioli S, Albanese C, Pesenti E, Finazzi MC et al. A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy. J Immunol 2014; 193:4739-47; PMID:25267972; http://dx.doi.org/10.4049/jimmunol.1401550
   PubMed Web of Science ®Google Scholar
• D'Arena G, Simeon V, De Martino L, Statuto T, D'Auria F, Volpe S, Deaglio S, Maidecchi A, Mattoli L, Mercati V et al. Regulatory T-cell modulation by green tea in chronic lymphocytic leukemia. Int J Immunopathol Pharmacol 2013; 26:117-25; PMID:23527714
   PubMed Web of Science ®Google Scholar
• Skorka K, Bhattacharya N, Wlasiuk P, Kowal M, Mertens D, Dmoszynska A, Giannopoulos K. Thalidomide regulation of NF-kappaB proteins limits Tregs activity in chronic lymphocytic leukemia. Adv Clin Exp Med 2014; 23:25-32; PMID:24596000; http://dx.doi.org/10.17219/acem/37018
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163:5211-8; PMID:10553041
   PubMed Web of Science ®Google Scholar
• Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30:825-30; PMID:18049334; http://dx.doi.org/10.1097/CJI.0b013e318156e47e
   PubMed Web of Science ®Google Scholar
• Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008; 93:193-200; PMID:18223287; http://dx.doi.org/10.3324/haematol.11702
   PubMed Web of Science ®Google Scholar
• Nunes C, Wong R, Mason M, Fegan C, Man S, Pepper C. Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin Cancer Res 2012; 18:678-87; PMID:22190592; http://dx.doi.org/10.1158/1078-0432.CCR-11-2630
   PubMed Web of Science ®Google Scholar
• Anand M, Chodda SK, Parikh PM, Nadkarni JS. Dysregulated cytokine production by monocytes from chronic lymphocytic leukemia patients. Cancer Biother Radiopharm 1998; 13:43-8; PMID:10850341; http://dx.doi.org/10.1089/cbr.1998.13.43
   PubMed Web of Science ®Google Scholar
• Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR, Mauri C. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007; 178:7868-78; PMID:17548625; http://dx.doi.org/10.4049/jimmunol.178.12.7868
   PubMed Web of Science ®Google Scholar